Brensocatib 10mg, 25mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10mg, 25mg

Reference Brands: Brinsupri (USA/EU)

Category: Respiratory Disorder

Brensocatib (brand name Brinsupri) is an orally-administered, once-daily small-molecule inhibitor of dipeptidyl peptidase 1 (DPP1), which in turn reduces activation of neutrophil serine proteases responsible for airway inflammation and tissue damage in chronic lung disease. It is indicated for treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 years and older, representing the first therapy specifically approved for this condition. In clinical trials, brensocatib reduced the annual rate of disease exacerbations and slowed lung function decline. Being the first in its class, it offers a novel mechanism targeting neutrophil-driven inflammation rather than purely the infection component.

Product Description:

Brensocatib is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1), the enzyme responsible for activating neutrophil serine proteases during neutrophil maturation in the bone marrow. By blocking that activation it reduces the destructive protease burden in the airway without depleting neutrophils themselves — an approach that addresses the underlying inflammatory mechanism rather than its consequences.

It was approved by the US FDA in August 2025 for non-cystic-fibrosis bronchiectasis in adults and adolescents from twelve years of age, and is the first therapy ever approved specifically for that condition. Bronchiectasis had, until this point, been managed entirely with treatments borrowed from other respiratory diseases. It is the first DPP1 inhibitor approved in any indication. Dosing is once daily at 10 mg or 25 mg.

Sourcing notes. This is a newly approved, on-patent innovator product from a single manufacturer. No generic exists and none can lawfully exist for years. Any offer of generic brensocatib should be refused and investigated. Approvals outside the United States were still progressing through the EU, UK and Japanese regulators through 2026, so availability is market-dependent and a product approved in one territory may have no route to import into another. Where a patient in an unapproved market requires it, the named-patient import pathway is the mechanism, and it requires the prescribing physician's documentation and the destination regulator's authorisation.